KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Accounts Payables (2023 - 2025)

Biocryst Pharmaceuticals' Accounts Payables history spans 9 years, with the latest figure at $15.8 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 35.92% year-over-year to $15.8 million; the TTM value through Dec 2025 reached $15.8 million, up 35.92%, while the annual FY2025 figure was $15.8 million, 35.92% up from the prior year.
  • Accounts Payables reached $15.8 million in Q4 2025 per BCRX's latest filing, up from $5.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $20.9 million in Q4 2023 to a low of $5.6 million in Q3 2025.
  • Average Accounts Payables over 3 years is $11.4 million, with a median of $11.1 million recorded in 2023.
  • Peak YoY movement for Accounts Payables: surged 90.44% in 2024, then plummeted 58.71% in 2025.
  • A 3-year view of Accounts Payables shows it stood at $20.9 million in 2023, then crashed by 44.27% to $11.6 million in 2024, then soared by 35.92% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Accounts Payables are $15.8 million (Q4 2025), $5.6 million (Q3 2025), and $8.6 million (Q2 2025).